Sarepta Therapeutics/$SRPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,372
ISIN
US8036071004
Website
SRPT Metrics
BasicAdvanced
$1.9B
-
-$2.59
0.84
-
Price and volume
Market cap
$1.9B
Beta
0.84
52-week high
$154.13
52-week low
$16.88
Average daily volume
6.4M
Financial strength
Current ratio
4.017
Quick ratio
1.952
Long term debt to equity
117.592
Total debt to equity
118.727
Interest coverage (TTM)
-6.26%
Profitability
EBITDA (TTM)
-78.252
Gross margin (TTM)
20.14%
Net profit margin (TTM)
-11.12%
Operating margin (TTM)
-5.25%
Effective tax rate (TTM)
-51.28%
Revenue per employee (TTM)
$1,630,000
Management effectiveness
Return on assets (TTM)
-2.19%
Return on equity (TTM)
-23.61%
Valuation
Price to revenue (TTM)
0.826
Price to book
1.65
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-2.644
Free cash flow yield (TTM)
-37.82%
Free cash flow per share (TTM)
-727.24%
Growth
Revenue change (TTM)
59.15%
Earnings per share change (TTM)
-1,538.31%
3-year revenue growth (CAGR)
42.87%
10-year revenue growth (CAGR)
89.86%
3-year earnings per share growth (CAGR)
-15.45%
10-year earnings per share growth (CAGR)
-4.57%
What the Analysts think about SRPT
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
Bulls say / Bears say
Sarepta Therapeutics has received approval from Japan's Ministry of Health, Labour and Welfare for ELEVIDYS, a gene therapy to treat Duchenne muscular dystrophy (DMD), marking the first global approval for treating patients younger than 4 years old, covering ages 3 to under 8 years. This approval is based on positive efficacy and safety data from clinical studies, including two-year results from the Phase 3 EMBARK trial, which demonstrated significantly better motor function outcomes compared to controls. Through a collaboration with Roche, Sarepta will receive up to $103.5 million in milestone payments. The therapy will be commercialized in Japan by Chugai Pharmaceuticals via its Roche alliance. ELEVIDYS is a single-dose, AAV-based gene therapy designed to address DMD's genetic cause through micro-dystrophin production in skeletal muscle. (stocktitan.net)
Sarepta's financials have been improving, with the company reporting $846.6 million in revenue through the first nine months of the year, a 25% increase from the same period last year. ELEVIDYS has already begun to contribute to the top line, with its sales totaling $69.1 million in the most recent quarter, which ended on Sept. 30. The company's operating loss of $20.8 million was just a fraction of the $131.4 million operating loss that Sarepta incurred a year ago. If it can expand ELEVIDYS' label, then that could help the company find a path to getting its financials into the black. At its peak, the therapy could bring in $4 billion in annual revenue with the label expansion. (fool.com)
Sarepta's CEO, Doug Ingram, stated that the company plans to move swiftly to request an update to expand the labeled indication to treat all patients, following the Phase 3 EMBARK study results. Although the primary endpoint was not met, the therapy achieved statistical significance on all key secondary endpoints across all age groups. Sarepta has already shared the EMBARK top-line results with the U.S. Food and Drug Administration (FDA), and according to Ingram, FDA leaders expressed an openness to expanding the label for ELEVIDYS to treat all DMD patients. (fool.com)
Sarepta Therapeutics has reported a second patient death linked to its gene therapy, ELEVIDYS, used to treat Duchenne's muscular dystrophy. The death, like the first in March, involved a teenage boy who suffered acute liver injury, a known side effect. Both fatalities involved older, non-ambulatory patients who receive higher doses of the therapy. In response, Sarepta has paused shipments and a study involving this group, and plans to implement stricter safety protocols, including increased use of immunosuppressants. The company is working with the FDA, which must approve any new safety measures. Following the latest death, Sarepta’s shares plummeted over 42%, and analysts speculate that tighter FDA restrictions or removal of the therapy for non-ambulatory patients could follow. (apnews.com)
The U.S. Food and Drug Administration (FDA) is investigating two recent deaths from acute liver failure in non-ambulatory Duchenne muscular dystrophy patients following treatment with Sarepta Therapeutics' gene therapy ELEVIDYS. The deceased were 15- and 16-year-old boys, both of whom died within 90 days of receiving the therapy. While ELEVIDYS’ U.S. prescribing information warns of acute liver injury, it does not indicate risks of liver failure or death. Approved in 2024 for ambulatory patients aged four and older, the therapy was conditionally approved for non-ambulatory patients despite not meeting the primary goal in a late-stage trial. Sarepta, who alerted the FDA and proposed updating the product label, has suspended its 2025 sales forecast for ELEVIDYS, paused shipments to non-ambulatory patients, and is cooperating with regulators to revise its treatment strategy. The FDA is evaluating possible further regulatory actions as Sarepta continues examining the two cases for shared risk factors. (reuters.com)
Sarepta Therapeutics' stock plummeted by 43.6% after the company announced top-line results from its Phase 3 EMBARK study evaluating ELEVIDYS in treating young patients with Duchenne muscular dystrophy (DMD). The primary endpoint of the late-stage study wasn't met, as patients receiving ELEVIDYS saw a 2.6-point improvement on the North Star Ambulatory Assessment (NSAA) total score 52 weeks after treatment, which was not statistically significant compared to the improvement experienced by patients receiving placebo. This raises concerns about the therapy's efficacy and potential market acceptance. (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
SRPT Financial Performance
Revenues and expenses
SRPT Earnings Performance
Company profitability
SRPT News
AllArticlesVideos
August 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SRPT
GlobeNewsWire·18 hours ago
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
GlobeNewsWire·20 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
GlobeNewsWire·22 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $1.9B as of July 15, 2025.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 0 as of July 15, 2025.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.